Latest Targeted therapy Stories
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill.,
Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/
Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs).
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Pathway Analysis Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 3, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused
Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and
Combined Gene and Protein Analysis of Sarcoma Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 2, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading
Large International Cohort of 17 GI Cancer Types Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 1, 2014 /PRNewswire/ -- Caris Life Sciences, a leading